In vivo XPO1 inhibition induces HCC tumor regression in mice
Feb. 5, 2024
Myc proto-oncogene protein (MYC) is a transcription factor that can modulate the transcription of several genes, and its overexpression has been found in many cancer types, including hepatocellular carcinoma (HCC). Its inhibition reverses tumorigenesis in vivo and it is a key therapeutic target in cancer. Stanford University scientists used CRISPR screening assays to identify several genes as downstream targets of MYC, including exportin-1 (XPO1), among others.